Tim Beyers

Is biotech getting unfairly ignored?

You're listening to Motley Fool Money.

Welcome, Fools.

I'm your host, Tim Beyers.

With me are two of my longtime Rule Breakers teammates, Carl Thiel and Tom King.

Thanks for being here, guys.

Yeah, it's great to be here.

Good to be here.

We're going to preview some biotech earnings.

We're also going to check in on one that reported this morning.

We're going to paint a picture of an industry that probably deserves a little bit more love, a little bit more attention.

Get your coffee ready because it's biotech time.

Let's talk about biotech approvals, Karl, and what's going on at the FDA.

It does seem as though things are a little bit, let's call it turbulent.

It does seem as though there was a warning from a former senior executive here.

I think this man's name is Richard Pasdor, who is the former longtime head of the oncology division.

I've often heard you talk about the JPMorgan conference, Carl, and how important it is to the biotech industry.

Sounds like he had some spicy things to say at that conference.

I mean, what's interesting here, and especially when you say that, it makes me wonder that some of the companies we would look at for the biotech side of the scorecard and Rule Breakers

that are dependent upon the FDA for fast approvals of promising drugs that are in clinical trials.